Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine

Abstract

Replacement of DTPw vaccination by Tritanrix-HB/Hib can be done without modifying the existing national immunization programs. This should facilitate widespread coverage of hepatitis B and Hib vaccinations and their rapid incorporation into the EPI.

Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen contentHaemophilus influenzaetype b vaccine in Filipino children

“…The results were within the range previously reported for Tritanrix TM -HepB. 15,17,[25][26][27][28] Together, the results show that reducing the thiomersal content of the DTPw-HBV component had no adverse effect on immunogenicity.…”

“…[12][13][14] GlaxoSmithKline (GSK) Biologicals licensed the first diphtheria-tetanus-whole cell pertussis-hepatitis B (DTPw-HBV) combination vaccine (Tritanrix TM -HepB) in 1996. 15 Originally formulated with thiomersal, a mercury-based compound widely used preservative in many vaccines, GSK Biologicals developed a DTPw-HBV formulation with reduced preservative content (DTPw-HBV LT ).…”

“…The percentage of primary and booster doses followed by local and general solicited symptoms was within the range reported for whole-cell pertussis vaccines. 15,26 No SAEs were considered to be related to vaccination. The results support post-marketing experience with Tritanrix TM -HepB in the Philippines.…”

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

“…8,9,[14][15][16][17][18] With respect to the comparison of post-immunization GMTs, there was a significant difference between the two groups for diphtheria, Hib and Hepatitis B antibodies, however, its clinical relevance is likely to be minimal, given the excellent percentage seroprotection. There was a significant increase in anti PRP IgG GMT following the booster dose (from 3.86 to 8.77 μg/ml in SIIL group).…”

Vacinação contra Haemophilus influenzae tipo b: proteção a longo prazo

“…The efficacy and safety of conjugate Hib vaccines has been proved by several investigations, even when associated or combined with other vaccines. 2,3 However, knowledge of the efficacy and safety of these vaccines is not enough for their large-scale implementation.…”